Bengaluru, India, 3rd November 2025: Remidio Innovative Solutions, a leader in AI-powered ophthalmic devices, today announced the launch of Neubo 130, a next-generation ultra-widefield neonatal retinal imaging system designed to enhance precision diagnostics for neonatal retinal conditions like Retinopathy of Prematurity (ROP).
India sees over three million premature births each year, translating to nearly 15 million retinal examinations if every baby is screened as per protocol. With the limited number of ROP specialists, it’s impossible to bridge this gap without technology.
Built to support clinicians working in both hospitals and NICUs, Neubo 130 combines innovative optical engineering with edge AI to assist in the detection of ROP in real time, even without internet connectivity.
With a 130° field of view, through-the-lens illumination, and light-shaping technology, Neubo 130 ensures uniform retinal brightness and exceptional peripheral visualisation, critical for identifying subtle changes in the newborn retina that guide timely treatment decisions.
Key highlights of the Neubo 130 include:
- Consistent peripheral detail (uniform illumination and reduced glare).
- Small-pupil imaging possible (high-quality imaging at pupils ≥3 mm).
- Bedside triage that’s instant, private, and standardized (offline AI assists ROP and plus-disease triage; standardized workflow reduces missed cases).
- Panoramic views with fewer retakes (auto-montage aligns multiple gazes into a single 130° composite)
- Built for collaborative care (telemedicine- and cloud-ready for secure review, triage, and referral)
“The launch of Neubo 130 marks a major step forward in neonatal eye care,” said Dr. Anand Sivaraman, CEO of Remidio. “This platform is our bet on certainty, reframing ROP from a resource problem to an engineering solution. By enabling dependable, on-the-spot decisions at the bedside, we move from ‘screening when possible’ to ‘protecting vision as standard’.
“With affordable imaging and AI-driven triage systems like Remidio’s NEUBO 130, we can bring early and accurate ROP detection to even the most remote centers. The future of screening is simple, intelligent, and accessible – empowering every healthcare worker to protect a baby’s vision from the very first exam.” – Dr. Anand Vinekar, Professor & Head, ROP Services, Narayana Nethralaya; Program Director, KIDROP.
With its lightweight design (below 500g), high-resolution imaging (2.4MP), and offline AI workflow, Neubo 130 extends Remidio’s mission to make eye care accessible, affordable, and scalable across all settings , from tertiary hospitals to SNCUs.
This innovation continues Remidio’s legacy of bringing Made-in-India medical technology to the global stage, reinforcing its presence across 55 countries and supporting over 16 million patients screened worldwide.
